# 2026-16960: FDA Drafts Potency Rules for Immune Therapy Power Plays

2026-16960, Potency Assessment of Active Immunotherapy Products; Draft Guidance for Industry; Availability, is a Federal Register notice from Health and Human Services Department, Food and Drug Administration published 2026-08-20, effective Submit either electronic or written comments on the draft guidance by November 18, 2026 to ensure that the Agency considers your comment on this draft guidance before it begins work on the final version of the guidance. (as of 2026-08-27).

- Canonical: https://policyrisk.com/federal-register/2026-16960
- As of: 2026-08-27
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2026-16960
- Title: Potency Assessment of Active Immunotherapy Products; Draft Guidance for Industry; Availability
- Type: Notice
- Agencies: Health and Human Services Department; Food and Drug Administration
- Citation: 91 FR 53880
- Published: 2026-08-20
- Effective: Submit either electronic or written comments on the draft guidance by November 18, 2026 to ensure that the Agency considers your comment on this draft guidance before it begins work on the final version of the guidance.
- Comments close: 2026-11-18
- Significant: no
- Touches household money: no
- Regulation identifier numbers: none
- Last updated: 2026-08-27

## In one line

FDA Drafts Potency Rules for Immune Therapy Power Plays

## Summary

The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft document titled "Potency Assessment of Active Immunotherapy Products." The draft guidance document provides recommendations for developing assays to assess potency as a part of a potency assurance strategy for active immunotherapy products (ACTIMPs). When finalized, this guidance will describe the FDA's current thinking regarding design, validation, and evaluation of potency tests for ACTIMPs. This guidance is intended to supplement the December 2023 draft guidance for industry, when finalized, on "Potency Assurance for Cellular and Gene Therapy Products" with additional advice and considerations specifically for ACTIMPs, including peptide- and-protein based ACTIMPs that are not cellular or gene therapy products.

## Effects PRIA read

No economic effects identified for this document.

## Related documents

- [2026-20848](https://policyrisk.com/federal-register/2026-20848): Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods, 2026-10-13
- [2026-16296](https://policyrisk.com/federal-register/2026-16296): Substances Generally Recognized as Safe, 2026-08-11
- [2026-14073](https://policyrisk.com/federal-register/2026-14073): Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign E…, 2026-07-13
- [2026-13047](https://policyrisk.com/federal-register/2026-13047): Establishment Registration and Product Listing for Tobacco Products, 2026-06-29
- [2025-04978](https://policyrisk.com/federal-register/2025-04978): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-03-25
- [2025-01840](https://policyrisk.com/federal-register/2025-01840): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-01-27

## Sources
- [2026-16960 on federalregister.gov](https://www.federalregister.gov/documents/2026/08/20/2026-16960/potency-assessment-of-active-immunotherapy-products-draft-guidance-for-industry-availability)
- [2026-16960 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2026-08-20/pdf/2026-16960.pdf)

## Related
- [Previous: 2026-16959, Frequently Asked Questions-Developing Potential Cellular and Gene Therapy Produ…](https://policyrisk.com/federal-register/2026-16959)
- [Next: 2026-16962, Codex Alimentarius Commission: Meeting of the Codex Committee on Pesticide Resi…](https://policyrisk.com/federal-register/2026-16962)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2026-16960 (as of 2026-08-27).
